Analyst firms · Mizuho · BIIB

Mizuho BIIB price target and rating history

Biogen Inc. (BIIB) · Health Care

Mizuho rates Biogen Inc. (BIIB) Buy with a $270 price target, as of its latest action on Sep 28, 2022. It has published 3 rating actions on BIIB since October 2021, including 1 upgrade and 0 downgrades. Across 10 firms with a BIIB price target in the last 12 months, the median target is $231.50.

Current rating
Buy
Price target
$270
Median target, all firms
$231.50
Actions on BIIB
3

Mizuho price target on BIIB

$270$239$20720222023202420252026
Mizuho price target on BIIB, each point a stated target, October 2021 to September 2022.

Every Mizuho rating on BIIB

How other firms rate BIIB

Each firm's latest rating and stated target in the last 12 months.

FirmRatingPrice targetDate
Argus ResearchBuy$280Oct 29, 2026
Wolfe ResearchOutperform$300Aug 13, 2026
Truist SecuritiesBuy$235Jul 13, 2026
NeedhamBuy$255Jun 8, 2026
Evercore ISIOutperformMay 15, 2026
UBSBuy$225Apr 22, 2026
Wells FargoOverweight$250Apr 20, 2026
Piper SandlerOverweight$214Apr 14, 2026
BarclaysEqual Weight$185Feb 20, 2026
H.C. WainwrightBuy$228Feb 9, 2026
HSBCReduce$143Dec 10, 2025

Questions about Mizuho and BIIB

What is Mizuho's price target for BIIB?
Mizuho's latest stated price target for Biogen Inc. (BIIB) is $270, from its action on Sep 28, 2022.
What is Mizuho's rating on BIIB?
Mizuho rates BIIB Buy, a bullish rating, as of Sep 28, 2022.
When did Mizuho last change its view on BIIB?
On Sep 28, 2022, Mizuho upgrades to Buy from Neutral, price target $207 to $270.
How does Mizuho's BIIB target compare with other analysts?
Across 10 firms with a BIIB price target in the last 12 months, the median target is $231.50.

More BIIB rating histories

All Mizuho ratingsBIIB news and filingsEvery analyst firm

From rating actions in the Quantisnow feed. A target holds until the firm states a new one; a reiteration with no target keeps the last one. Not investment advice.